What We're Reading
Industry reads hand-picked by our editors
Apr 19, 2024
-
The Atlantic
The Bone-Marrow-Transplant Revolution
-
Bloomberg
Seasonal Allergies Are Getting Worse Because of Global Warming
-
Reuters
China’s drugmakers can’t sell mRNA shots but haven’t quit yet
-
The Wall Street Journal
Influencers Love Ozempic—but They Aren’t Telling You About the Risks
Apr 18, 2024
-
The Washington Post
Cancer could soon be detected by blood tests, even before symptoms
-
CNN
‘Kids need to breathe just like adults do:’ $35 price caps don’t apply to asthma meds young children need, doctors say
-
BioCentury
Drive-by analysis of accelerated approval is intellectual malpractice
-
Time
Stuart Orkin is on the 2024 TIME100 List
Apr 17, 2024
Apr 16, 2024
Apr 15, 2024
-
The New York Times
U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
-
Bloomberg
Cancer, ALS Drugs That Don’t Work Are Costing Americans Billions
-
The Wall Street Journal
Two Brothers, a Big Biotech Bet and an $8 Billion Payout
Apr 12, 2024
-
Bloomberg
Nuclear Medicine Is Big Pharma’s New Target in Cancer Race
-
Financial Times
Drugmakers race to find alternative suppliers as US cracks down on Chinese biotech
-
Stat
New precision technique helped guide pediatric cancer regimen
-
The Washington Post
Former NIH director Collins on his prostate cancer, medical research
Apr 11, 2024
-
Axios
Drug shortages reach all-time high
-
Financial Times
Moderna puts plans for African vaccine plant on hold
-
ApexOnco
Arvinas degraders get another vote of confidence
-
Bloomberg
Birth Control Has a TikTok Problem